The table below shows BIOCRYST PHARMACEUTICALS INC's cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
Line item
Q1 2026
Q1 2025
Q1 2024
Q1 2023
Q1 2022
Q1 2021
Operating cash flow
-$61.79M
-$27.52M
-$53.68M
-$47.51M
-$77.80M
-$61.01M
Capital expenditure
-
-
-
-
-
-
Investing cash flow
-$268.65M
$27.09M
$28.76M
-$107.11M
-$38.47M
$14.67M
Dividends paid
-
-
-
-
BCRX operating cash flow (10-K history)
BIOCRYST PHARMACEUTICALS INC reported operating cash flow of $347.37M for fiscal year 2025. That is up 767.8% from -$52.02M in fiscal 2024. Over the 10 fiscal years shown, operating cash flow grew from -$53.44M (FY 2016) to $347.37M. Figures come from the company's audited annual reports as filed with the SEC.
